12 completed. 11 Not applicable, 1 Phase 1.
By phase and status
Follow ADIUM: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed Conditions
Tamsulosin 0.4 mg ER tablet - Bioequivalence | Not applicable | Completed | 66 | 2026-02-12 | 2026-07-13 |
Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions
TAMSULOSIN TEST, OMNIC OCAS REFERENCE - Bioequivalance | Not applicable | Completed | 34 | 2026-01-12 | 2026-07-13 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.
Janumet XR, Sitagliptin/Metformin FDC - Bioequivalance | Not applicable | Completed | 46 | 2025-12-08 | 2026-08-14 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.
Janumet XR, Sitagliptin/Metformin FDC - Bioequivalance | Not applicable | Completed | 46 | 2025-12-03 | 2026-08-14 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.
Janumet XR, Sitagliptin/Metformin FDC - Bioequivalence | Not applicable | Completed | 46 | 2025-11-24 | 2026-08-14 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.
Sitagliptin/Metformin FDC, Janumet XR - Bioequivalance | Not applicable | Completed | 46 | 2025-11-19 | 2026-08-14 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets Under Fed Conditions.
Synjardy 5/850 mg tablet, Reference, Empagliflozin/metformin 12.5/500 mg test - Bioequivalence Study in Healthy Subjects | Not applicable | Completed | 42 | 2025-09-10 | 2026-06-10 |
Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions
Reference, Test - Bioequivalance | Phase 1 | Completed | 20 | 2025-03-18 | 2026-06-03 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions.
Test. Empagliflozin/metformin 5/850 mg, Synjardy 5/850 mg tablet, Reference - Bioequivalence Study in Healthy Subjects | Not applicable | Completed | 42 | 2025-02-17 | 2026-06-10 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 850 mg Tablets Under Fed Conditions.
Empagliflozin/metformin 12.5/850 mg tablet (test), Synjardy 12.5/850 mg tablet (Reference) - Bioequivalence Study in Healthy Subjects | Not applicable | Completed | 42 | 2025-02-10 | 2026-06-10 |
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.
Synjardy 12.5/1000 mg tablet, Empagliflozin/metformin 12.5/1000 mg - Bioequivalence Study in Healthy Subjects | Not applicable | Completed | 42 | 2025-02-05 | 2026-06-10 |
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
Empagliflozin (Jardiance®), Empagliflozin (oral) - Bioequivalance | Not applicable | Completed | 32 | 2024-11-29 | 2026-03-18 |
Interventions
Metformin (7) · Sitagliptin Phosphate (4) · Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination (4) · Tablets (4) · empagliflozin (4) · Tamsulosin (1)
Countries
Mexico (12)
Results publications
PMID 42653697, PMID 42654125, PMID 42515774